Cryo-Cell Price to Free Cash Flow Ratio 2010-2024 | CCEL

Cryo-Cell price to free cash flow ratio from 2010 to 2024. Price to free cash flow ratio can be defined as

Cryo-Cell Price to Free Cash Flow Ratio 2010-2024 | CCEL

Cryo-Cell price to free cash flow ratio from 2010 to 2024. Price to free cash flow ratio can be defined as
Related Stocks
Company NameMarket
Cap
Elevance Health (ELV)$95.8B
Cencora (COR)$49B
DiDi Global (DIDIY)$23.3B
ICON (ICLR)$17.5B
Natera (NTRA)$16.7B
Viatris (VTRS)$15.4B
Avantor (AVTR)$14.8B
Revvity (RVTY)$14.6B
BioMerieux (BMXMF)$12.9B
CochLear (CHEOY)$12.7B
Solventum (SOLV)$12.2B
Medpace Holdings (MEDP)$11.2B
Charles River Laboratories (CRL)$11B
Doximity (DOCS)$10.8B
HealthEquity (HQY)$8.7B
Sonic Healthcare (SKHHY)$8.5B
Bausch + Lomb (BLCO)$6.9B
Life Times (LTH)$5B
Sotera Health (SHC)$4.4B
Organon (OGN)$4B
Surgery Partners (SGRY)$3.8B
BrightSpring Health Services (BTSG)$3.4B
PACS (PACS)$3.1B
Concentras Parent (CON)$2.6B
Alignment Healthcare (ALHC)$2.5B
Ardent Health Partners (ARDT)$2.4B
Premier (PINC)$2.3B
GeneDx Holdings (WGS)$2.1B
Ryman Healthcare (RYHTY)$2B
GoodRx Holdings (GDRX)$1.8B